CL2020000017A1 - Composición novedosa de la forma de dosificación oral de la enzalutamida y su método de fabricación. - Google Patents

Composición novedosa de la forma de dosificación oral de la enzalutamida y su método de fabricación.

Info

Publication number
CL2020000017A1
CL2020000017A1 CL2020000017A CL2020000017A CL2020000017A1 CL 2020000017 A1 CL2020000017 A1 CL 2020000017A1 CL 2020000017 A CL2020000017 A CL 2020000017A CL 2020000017 A CL2020000017 A CL 2020000017A CL 2020000017 A1 CL2020000017 A1 CL 2020000017A1
Authority
CL
Chile
Prior art keywords
enzalutamide
dosage form
oral dosage
novel composition
manufacture
Prior art date
Application number
CL2020000017A
Other languages
English (en)
Spanish (es)
Inventor
Manappa Badiger Aravind
Ketanbhai Choksi Rakshit
Naginbhai Patel Bhavesh
Sharad Salunkhe Piyusha
Ramnivedan Soni Niraj
Mahendrabhai Shah Dharmesh
Original Assignee
Bdr Pharmaceuticals International Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64950639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bdr Pharmaceuticals International Private Ltd filed Critical Bdr Pharmaceuticals International Private Ltd
Publication of CL2020000017A1 publication Critical patent/CL2020000017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2020000017A 2017-07-04 2020-01-03 Composición novedosa de la forma de dosificación oral de la enzalutamida y su método de fabricación. CL2020000017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721023465 2017-07-04

Publications (1)

Publication Number Publication Date
CL2020000017A1 true CL2020000017A1 (es) 2020-05-22

Family

ID=64950639

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000017A CL2020000017A1 (es) 2017-07-04 2020-01-03 Composición novedosa de la forma de dosificación oral de la enzalutamida y su método de fabricación.

Country Status (7)

Country Link
BR (1) BR112020000207A2 (fr)
CL (1) CL2020000017A1 (fr)
MX (1) MX2020000213A (fr)
PH (1) PH12020500045A1 (fr)
RU (1) RU2020105102A (fr)
WO (1) WO2019008426A1 (fr)
ZA (1) ZA202000609B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200015830A (ko) * 2014-02-05 2020-02-12 레크 파마슈티칼스 디.디. 안드로겐 수용체 길항제의 고체 제약 조성물

Also Published As

Publication number Publication date
BR112020000207A2 (pt) 2020-07-07
WO2019008426A1 (fr) 2019-01-10
MX2020000213A (es) 2020-08-17
PH12020500045A1 (en) 2020-11-09
RU2020105102A (ru) 2021-08-04
ZA202000609B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CO2018000350A2 (es) Forma cristalina de la plinabulina monohidratada, composiciones que la comprenden y procedimientos de elaboración
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
NI201500177A (es) Formulación en perlas de cisteamina de liberación retardada
CL2018002519A1 (es) Procedimiento para fabricar una lechada de cal apagada de gran finura y lechada de cal de gran finura obtenida con agua de proceso
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
CA164082S (en) Dental capsule
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
BR112016019389A2 (pt) vacina, e, peptídeo
BR112017014085A2 (pt) processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
EP3826609A4 (fr) Forme pharmaceutique structurée expansible
IN2013MU01985A (fr)
IT201700085789A1 (it) Metodo per la preparazione di rucaparib ad elevata purezza
AR113695A1 (es) Una d-psicosa 3-epimerasa y el uso de un método para producir d-psicosa
DK3773511T3 (da) Oral tablet til induceret spytproduktion
CL2020000017A1 (es) Composición novedosa de la forma de dosificación oral de la enzalutamida y su método de fabricación.
CL2018002149A1 (es) Proceso.
IN2014DN06617A (fr)
TR201722603A2 (tr) Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari